{"entity":{"id":"nct05952037","kind":"trial","name":"A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia","aka":[],"tldr":"A phase 2 trial of Sonrotoclax and Zanubrutinib in waldenström macroglobulinaemia, run by BeOne Medicines, active and no longer recruiting.","summary":"A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia is a phase 2 interventional study registered as NCT05952037 by BeOne Medicines, with 114 participants enrolled, started 2023-10-23 and due to reach its primary completion in 2026-09-22. Interventions recorded: Sonrotoclax and Zanubrutinib.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05952037","url":"https://clinicaltrials.gov/study/NCT05952037"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["waldenstrom"],"sections":[],"technologies":["bcl2-inhibitors","kinase-inhibitors"],"targets":[],"drugs":["sonrotoclax","zanubrutinib"],"companies":["beone"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05952037","phase":"2","setting":"An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination With Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia","sponsor":"BeOne Medicines","participation":[{"nct":"NCT05952037","source":"https://clinicaltrials.gov/study/NCT05952037","fetchedAt":"2026-10-07T16:54:02.117Z","studySha256":"d4cad8fc6ca3bc686c427496131558a0b58a06785050505a9cf8a7f3f8cc672d","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-01-02","leadSponsor":"BeOne Medicines","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":114,"enrolmentType":"ACTUAL","siteCount":72,"recruitingSiteCount":0,"countries":["Australia","Canada","China","France","Greece","Italy","Spain","United Kingdom","United States"]}],"started":"2023-10-23","startedType":"actual","enrolled":114,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05952037/","neighbours":{"cancer":[{"id":"waldenstrom","kind":"cancer","name":"Waldenström macroglobulinaemia","route":"/cancers/waldenstrom/"}],"technology":[{"id":"bcl2-inhibitors","kind":"technology","name":"BCL-2 inhibitors","route":"/technologies/bcl2-inhibitors/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"sonrotoclax","kind":"drug","name":"Sonrotoclax","route":"/drugs/sonrotoclax/"},{"id":"zanubrutinib","kind":"drug","name":"Zanubrutinib","route":"/drugs/zanubrutinib/"}],"company":[{"id":"beone","kind":"company","name":"BeOne Medicines (formerly BeiGene)","route":"/companies/beone/"}]}}